KYMR (STOCKS)
Kymera Therapeutics, Inc. Common Stock
$82.270000
+2.780000 (+3.50%)
Prev close: $79.490000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Nello Mainolfi
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $6,501.45M
- Employees
- 225
- P/E (TTM)
- -22.88
- P/B (TTM)
- 6.24
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $43.74M |
| Benefits Costs and Expenses | $338.86M |
| Cost Of Revenue | $43.74M |
| Costs And Expenses | $338.86M |
| Gross Profit | $0.00 |
| Operating Expenses | $375.99M |
| Research and Development | $304.55M |
| Other Operating Expenses | $71.44M |
| Operating Income/Loss | -$332.26M |
| Income/Loss From Continuing Operations After Tax | -$295.12M |
| Income/Loss From Continuing Operations Before Tax | -$295.12M |
| Net Income/Loss | -$295.12M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$295.12M |
| Net Income/Loss Available To Common Stockholders, Basic | -$295.12M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.60 |
| Diluted Earnings Per Share | -$3.60 |
| Basic Average Shares | 84,366,795 |
| Diluted Average Shares | 84,366,795 |
| Assets | $1.10B |
| Current Assets | $528.30M |
| Noncurrent Assets | $573.75M |
| Fixed Assets | $45.13M |
| Other Non-current Assets | $528.62M |
| Liabilities | $155.79M |
| Current Liabilities | $71.58M |
| Accounts Payable | $5.51M |
| Other Current Liabilities | $66.07M |
| Noncurrent Liabilities | $84.21M |
| Equity | $946.26M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $946.26M |
| Liabilities And Equity | $1.10B |
| Net Cash Flow From Operating Activities | -$227.93M |
| Net Cash Flow From Operating Activities, Continuing | -$227.93M |
| Net Cash Flow From Investing Activities | -$58.10M |
| Net Cash Flow From Investing Activities, Continuing | -$58.10M |
| Net Cash Flow From Financing Activities | $288.26M |
| Net Cash Flow From Financing Activities, Continuing | $288.26M |
| Net Cash Flow | $2.24M |
| Net Cash Flow, Continuing | $2.24M |
| Comprehensive Income/Loss | -$295.55M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$295.55M |
| Other Comprehensive Income/Loss | -$430.00K |